Maki Ando

1.5k total citations · 1 hit paper
20 papers, 1.2k citations indexed

About

Maki Ando is a scholar working on Oncology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Maki Ando has authored 20 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Molecular Biology and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Maki Ando's work include Cancer therapeutics and mechanisms (9 papers), Neonatal Health and Biochemistry (5 papers) and Lung Cancer Research Studies (5 papers). Maki Ando is often cited by papers focused on Cancer therapeutics and mechanisms (9 papers), Neonatal Health and Biochemistry (5 papers) and Lung Cancer Research Studies (5 papers). Maki Ando collaborates with scholars based in Japan, Netherlands and China. Maki Ando's co-authors include Yukio Ando, Yoshinori Hasegawa, Kaoru Shimokata, Hideo Saka, Akira Yokoyama, Kei Muro, Soh Saitoh, Toshiyuki Sawa, Hiroshi Ueoka and Mitsuhiro Endoh and has published in prestigious journals such as Journal of Clinical Oncology, Annals of the New York Academy of Sciences and Clinical Chemistry.

In The Last Decade

Maki Ando

20 papers receiving 1.2k citations

Hit Papers

Polymorphisms of UDP-glucuronosyltransferase gene and iri... 2000 2026 2008 2017 2000 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
    2000 607 citations Yukio Ando, Hideo Saka et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maki Ando Japan 12 627 622 242 230 188 20 1.2k
Hayakazu Nakazawa Japan 20 698 1.1× 339 0.5× 166 0.7× 79 0.3× 101 0.5× 64 1.7k
N A Brophy United States 10 759 1.2× 429 0.7× 246 1.0× 50 0.2× 78 0.4× 13 1.2k
Michael Eschenberg United States 12 740 1.2× 362 0.6× 106 0.4× 290 1.3× 181 1.0× 16 1.7k
Ian F. Faneyte Netherlands 14 1.3k 2.1× 476 0.8× 349 1.4× 33 0.1× 102 0.5× 18 1.9k
Marie‐Hélène Schlageter France 19 421 0.7× 342 0.5× 431 1.8× 46 0.2× 142 0.8× 39 1.4k
Marcel Soesan Netherlands 12 462 0.7× 237 0.4× 57 0.2× 52 0.2× 108 0.6× 23 912
Torben Stamm Mikkelsen Denmark 13 388 0.6× 251 0.4× 343 1.4× 40 0.2× 125 0.7× 37 1.1k
Elena Guerini Switzerland 15 208 0.3× 191 0.3× 68 0.3× 227 1.0× 81 0.4× 29 793
Song Ren China 13 256 0.4× 155 0.2× 65 0.3× 105 0.5× 130 0.7× 33 953
J Nataf France 11 249 0.4× 264 0.4× 89 0.4× 52 0.2× 101 0.5× 15 1.3k

Countries citing papers authored by Maki Ando

Since Specialization
Citations

This map shows the geographic impact of Maki Ando's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maki Ando with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maki Ando more than expected).

Fields of papers citing papers by Maki Ando

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maki Ando. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maki Ando. The network helps show where Maki Ando may publish in the future.

Co-authorship network of co-authors of Maki Ando

This figure shows the co-authorship network connecting the top 25 collaborators of Maki Ando. A scholar is included among the top collaborators of Maki Ando based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maki Ando. Maki Ando is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ikeguchi, Ryosuke, et al.. (2022). Anterolateral thigh flap for upper extremity reconstruction in older patients. Microsurgery. 42(8). 793–799. 1 indexed citations
2.
3.
Kondo, Masashi, Maki Ando, Hiroshi Saito, et al.. (2012). Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.. PubMed. 74(1-2). 133–40. 36 indexed citations
4.
Hirashima, T., Isamu Okamoto, Hiroshige Yoshioka, et al.. (2011). Phase III study comparing the effects of carboplatin plus S-1 and carboplatin plus paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer: An updated report of the LETS study (WJTOG3605).. Journal of Clinical Oncology. 29(15_suppl). 7552–7552. 2 indexed citations
5.
Goto, Masaki, Kenji Wakai, Takeshi Kawamura, et al.. (2009). A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrology Dialysis Transplantation. 24(10). 3068–3074. 190 indexed citations
6.
Tamura, Kaoru, Chikako Shimizu, Fumiaki Koizumi, et al.. (2009). Correlation of FcγR IIa-H131R and IIIa-V158F polymorphisms and clinical outcome of trastuzumab in both neoadjuvant and metastatic setting in patients with HER-2 positive breast cancer. Journal of Clinical Oncology. 27(15_suppl). 1100–1100. 3 indexed citations
7.
Goto, Masaki, Takeshi Kawamura, K. Wakai, et al.. (2008). Risk stratification for progression of IgA nephropathy using a decision tree induction algorithm. Nephrology Dialysis Transplantation. 24(4). 1242–1247. 46 indexed citations
8.
Hasegawa, Yoshinori, Yukio Ando, Maki Ando, et al.. (2006). Pharmacogenetic Approach for Cancer Treatment–Tailored Medicine in Practice. Annals of the New York Academy of Sciences. 1086(1). 223–232. 10 indexed citations
9.
Kitagawa, Chiyoe, Maki Ando, Yukio Ando, et al.. (2005). Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenetics and Genomics. 15(1). 35–41. 46 indexed citations
10.
Ando, Maki, Yoshinori Hasegawa, & Yukio Ando. (2005). Pharmacogenetics of irinotecan: A promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan. Investigational New Drugs. 23(6). 539–545. 21 indexed citations
11.
Ando, Maki, Hideo Saka, Yukio Ando, et al.. (2005). Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences. Cancer Chemotherapy and Pharmacology. 55(6). 552–558. 11 indexed citations
12.
Hasegawa, Yoshinori, Maki Ando, Chiyoe Kitagawa, et al.. (2004). Rapid Detection of UGT1A1 Gene Polymorphisms by Newly Developed Invader Assay. Clinical Chemistry. 50(8). 1479–1480. 37 indexed citations
13.
14.
Kitagawa, Chiyoe, Maki Ando, Yukio Ando, et al.. (2004). Genetic polymorphisms of the multidrug resistance-associated protein 2 gene (ABCC2) and Irinotecan toxicity. Journal of Clinical Oncology. 22(14_suppl). 2009–2009. 9 indexed citations
15.
Ando, Maki, Yukio Ando, Yoshitaka Sekido, et al.. (2002). Genetic Polymorphisms of the UDP‐Glucuronosyltransferase 1A7 Gene and Irinotecan Toxicity in Japanese Cancer Patients. Japanese Journal of Cancer Research. 93(5). 591–597. 50 indexed citations
16.
17.
Sato, Mitsuo, Masahiko Ando, Hironobu Minami, et al.. (2001). Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer. Cancer Chemotherapy and Pharmacology. 48(6). 481–487. 8 indexed citations
18.
Ando, Yukio, Hideo Saka, Maki Ando, et al.. (2000). Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.. PubMed. 60(24). 6921–6. 607 indexed citations breakdown →
19.
Ando, Maki, Hironobu Minami, Yukio Ando, et al.. (2000). Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level.. PubMed. 6(12). 4733–8. 38 indexed citations
20.
Ando, Maki, et al.. (1999). Pharmacological analysis of etoposide in elderly patients with lung cancer.. PubMed. 5(7). 1690–5. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hayakazu Nakazawa Breakdown of academic impact, for papers by N A Brophy Breakdown of academic impact, for papers by Michael Eschenberg Breakdown of academic impact, for papers by Ian F. Faneyte Breakdown of academic impact, for papers by Marie‐Hélène Schlageter Breakdown of academic impact, for papers by Marcel Soesan Breakdown of academic impact, for papers by Torben Stamm Mikkelsen Breakdown of academic impact, for papers by Elena Guerini Breakdown of academic impact, for papers by Song Ren Breakdown of academic impact, for papers by J Nataf
Rankless by CCL
2026